378 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
and responsibilities to the reasonable satisfaction of the Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
assigned duties and responsibilities to the reasonable satisfaction of the Board, which failure continues, in the reasonable judgment of the Board, for 30
8-K
EX-3.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon … requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
Warrants and the Aggregate Purchase Amount for such Purchaser shall be reduced accordingly.
2.2 Closing. Subject to the satisfaction or waiver … registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
. The PIPE financing is expected to close on or about September 13, 2024, subject to satisfaction of customary closing conditions.
The Company intends … -looking statements. These risks and uncertainties include, but are not limited to, market conditions and the satisfaction of closing conditions, as well
8-K
EX-4.1
roonl
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
8-K
vhu 8magerv
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.2
zc6emd
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.4
qeubucmu3
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-10.10
m35 haasmzjgbnof3
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.5
9rlmvo95308oe5
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-3.6
dk1uir31 tlw
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.3
fy2x7hg4criw8vix mk
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-3.9
x87hco7
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
EX-99.1
hpprnd nrs2zd4
26 Aug 24
Business combination disclosure
7:53pm
8-K
EX-99.1
qgfu8t9v51
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
j9vhr
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
5b8apv omaf7s6iq
16 Aug 24
Business combination disclosure
4:27pm
425
EX-99.1
nkwv71z678 qwyac
16 Aug 24
Business combination disclosure
4:27pm
8-K
2outvs y1qknu68
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm